Clinical Trials
50 trialsNCT00602667 2026-05-19
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT01257594 2023-05-25
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00871923 2021-09-16
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02239952 2020-10-08
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT00509431 2020-07-31
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01182350 2019-09-04
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT01103375 2018-08-01
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02655536 2018-07-10
BRILLIANT
National Taiwan University Hospital
Phase 2 Unknown
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00187486 2017-09-05
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
University of California, San Francisco
Phase 2 Completed
NCT00045110 2017-08-17
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00086879 2017-07-27
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00445588 2016-04-27
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301418 2016-02-10
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
Phase 1/2 Completed
NCT00124657 2015-12-04
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
St. Jude Children's Research Hospital
Phase 1/2 Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00112736 2015-06-15
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01578668 2015-01-26
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Guangzhou Medical University
Phase 2 Completed
NCT01763385 2014-12-23
TRACTS
Wu Jieping Medical Foundation
Phase 2 Unknown
NCT00525525 2014-11-14
AVF4120s
University of California, San Francisco
Phase 2 Completed
NCT00609999 2014-07-16
Ph I Dasatinib + Erlotinib in Recurrent MG
Duke University
Phase 1 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00337883 2014-03-04
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Genentech, Inc.
Phase 2 Completed
NCT00054496 2014-01-10
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00360854 2013-09-20
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00385398 2013-09-02
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00039494 2013-08-02
Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077454 2013-06-05
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00387894 2013-06-04
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
University of California, San Francisco
Phase 2 Terminated
NCT00671970 2013-05-13
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00274833 2012-12-06
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn
NCT00227032 2012-03-06
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00554775 2011-12-12
TACTIC
University College, London
Phase 2 Terminated
NCT00830245 2011-07-26
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Clinical Research Center for Solid Tumor, Korea
Phase 2 Terminated
NCT01158170 2010-07-08
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT01130779 2010-05-26
The Continuation of Erlotinib
Samsung Medical Center
Phase 2 Unknown
NCT00418327 2009-08-07
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT00536861 2008-05-29
Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00663689 2008-04-22
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
GuangdongPPH
Phase 2 Unknown